Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,900.40 -937.44 (-1.45%) CMC Crypto 200
1,331.31 -65.23 (-4.67%)
Biocon Limited (BIOCON.NS)
| Previous close | 291.65 |
| Open | 292.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 292.00 - 313.40 |
| 52-week range | 217.50 - 313.40 |
| Volume | |
| Avg. volume | 7,419,494 |
| Market cap | 366.764B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 30.55 |
| EPS (TTM) | 10.03 |
| Earnings date | 16 May 2024 |
| Forward dividend & yield | 1.50 (0.51%) |
| Ex-dividend date | 07 Jul 2023 |
| 1y target est | 282.61 |
ReutersIndia's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
- Reuters
UPDATE 1-Bristol Myers CEO says India to have largest R&D presence outside US by 2025
U.S. drugmaker Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the U.S. by 2025, CEO Christopher Boerner said on Tuesday. The $100-million facility, inaugurated by Boerner on Monday, is expected to employ over 1,500 employees and will be used to enhance its drug development through the use of digital technologies and artificial intelligence, he said in his keynote speech at the BioAsia conference. Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International.
- Reuters
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns
Indian biopharmaceutical company Biocon Ltd swung to a third-quarter profit on Thursday, boosted by its biosimilars business and the sale of some of its non-core units, and said Chief Financial Officer Indranil Sen had resigned. Sen, who has been with the company for nearly a decade, resigned from the role to pursue career opportunities outside of Biocon, it said. For the latest quarter, the Bengaluru-based company reported a consolidated net profit of 6.6 billion rupees ($79.6 million), compared with a loss of 418 million rupees a year earlier.
